Organisation paid for research Program year 2025 Source: CMS Open Payments

Florida Urology Partners LLP

Neither a doctor nor a teaching hospital

Research payments

$157,136

33 payments

Through program year 2025, Florida Urology Partners LLP is reported as receiving $157,136 in research payments, across 33 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $57,935 4
2024 Research $7,978 4
2023 Research $45,887 8
2022 Research $3,213 2
2021 Research $21,396 7
2020 Research $16,822 5
2019 Research $3,905 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teleflex LLC $56,025 2 payments
  2. Sumitomo Pharma America, Inc. $33,248 7 payments
  3. Medtronic USA, Inc. $20,727 8 payments
  4. Medtronic, Inc. $18,982 8 payments
  5. Boston Scientific Corporation $13,177 6 payments
  6. Veru Inc. $9,350 1 payment
  7. Pfizer Inc. $5,627 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Barrigel Prostate Trial $56,025 2 payments
  2. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $22,772 3 payments
  3. Elite $18,982 8 payments
  4. Sabre $13,177 6 payments
  5. BASIC Study $10,396 3 payments
  6. Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $9,350 1 payment
  7. SNM Trial Phase 2 Study $9,121 3 payments
  8. A Phase 3 Multinational Randomized Openlabel Three Parallelarm Study of Pf06801591 An Antipd1 Antibody in Combination With Bacillus Calmetteguerin BCG Induction With Or Without BCG Maintenance Versus BCG Induction and Maintenance in Participants With Highrisk Bcgnaive Nonmuscle Invasive Bladder Cancer $5,627 1 payment
  9. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $5,476 3 payments
  10. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record